Twice-weekly carfilzomib (27 mg/m2) plus lenalidomide and dexamethasone (KRd27) is a standard of care in relapsed/refractory multiple myeloma (RRMM). Once-weekly carfilzomib regimens have shown clinical benefits with improved patient convenience. This open-label, phase 3, multicenter, randomized study aimed to demonstrate noninferiority of the overall response rate (ORR) for once-weekly carfilzomib (56 mg/m2) plus Rd (KRd56) vs twice-weekly KRd27 in RRMM. A total of 454 patients were randomized (1:1) to receive carfilzomib as once-weekly 30-minute infusions of 56 mg/m2 (KRd56; n = 228) or twice-weekly 10-minute infusions of 27 mg/m2 (KRd27; n = 226). Baseline characteristics were balanced between groups. ORR was 82.5% (95% confidence interval [CI], 76.9-87.2) in the once-weekly group vs 86.3% (95% CI, 81.1-90.5) in the twice-weekly group (risk ratio, 0.954 [95% CI, 0.882-1.032]) and did not meet the threshold for statistical significance of noninferiority (P = .0666). Complete response (CR) or better was obtained in 46.9% of patients in the once-weekly arm and 36.3% in the twice-weekly arm. The proportions of patients who achieved CR and were also assessed negative for minimal residual disease were 21.5% and 18.1%, respectively (odds ratio, 1.235 [95% CI, 0.775-1.970]). Progression-free survival was comparable between groups (hazard ratio, 0.945 [95% CI, 0.617-1.447]). The safety profile was similar for both groups. In conclusion, although statistical significance for noninferiority of ORR was not achieved, the efficacy and safety of once-weekly KRd56 were similar to those of twice-weekly KRd27, and once-weekly KRd56 may be an effective and convenient treatment option for patients with RRMM. This trial was registered at www.ClinicalTrials.gov as #NCT03859427.

1st Department of Medicine Department of Hematology 1st Faculty of Medicine Charles University and General Hospital Prague Czech Republic

Amgen Inc Thousand Oaks CA

Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Athens Greece

Department of Haematology Carol Davila University of Medicine and Pharmacy Bucharest Romania

Department of Hematology and Bone Marrow Transplantation Unit Evangelismos Hospital Athens Greece

Department of Hematology and Cellular Therapy CIC U1402 CHU de Poitiers Poitiers France

Department of Hematology Fundeni Clinical Institute Bucharest Romania

Hematology Ankara Liv Hospital Istinye University Ankara Turkey

Oncology Hematology Care Inc Cincinnati OH

Zobrazit více v PubMed

Martínez Cordero H, Zapata Malagon J, Cubillos Osorio L, et al. Multiple myeloma mortality incidence prevalence of disease - Mmy Mind Study. Blood. 2020;136(suppl 1):10–11.

Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 2016;51(4):479–491. PubMed PMC

Sonneveld P, De Wit E, Moreau P. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Crit Rev Oncol Hematol. 2017;112:153–170. PubMed

Nijhof IS, van de Donk NWCJ, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19–37. PubMed PMC

Kyprolis (carfilzomib). Package insert. Amgen Inc; 2022.

Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728–734. PubMed

Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152. PubMed

Barrett-Lee P, Bloomfield D, Dougherty L, et al. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin. 2007;23(7):1575–1582. PubMed

Moreau P, Mateos M-V, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953–964. PubMed

Chari A, Martinez-Lopez J, Mateos M-V, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(5):421–431. PubMed PMC

Dimopoulos M, Quach H, Mateos M-V, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197. PubMed

Biran N, Siegel D, Berdeja JG, et al. Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a phase 1b study. Am J Hematol. 2019;94(7):794–802. PubMed PMC

Gruchet C, Moya N, Sabirou F, et al. Effect of prolonged treatment with carfilzomib, lenalidomide and dexamethasone in relapsed and refractory multiple myeloma. Poster presented at: EHA Annual Meeting (virtual) 11-14 June 2020

US National Library of Medicine; ClinicalTrials.gov A study comparing once-weekly vs twice-weekly carfilzomib in combination with lenalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (ARROW2). ClinicalTrials.gov identifier: NCT03859427. https://clinicaltrials.gov/study/NCT03859427

Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143–e161. PubMed

FDA Non-inferiority clinical trials to establish effectiveness. Guidance for industry. 2016. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/non-inferiority-clinical-trials

EMA Guideline on the choice of the non-inferiority margin. 2005. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-choice-non-inferiority-margin_en.pdf

Berenson JR, Cartmell A, Bessudo A, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127(26):3360–3368. PubMed PMC

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03859427